Calendrier des promotions Tiziana Life Sciences Ltd
Calendrier avancé
Graphique simple
À propos de l'entreprise Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Paramètres de base
IPO date
2000-03-24
ISIN
BMG889121031
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 0 | 0 |
P/BV | 19.72 | 1 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -101.1 | 0 |
ROE | -250.49 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.0161 | 10 |
Debt/Ratio | 0.0219 | 10 |
Debt/Equity | 1.87 | 7 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | -97.64 | 0 |
Rentabilité Ebitda, % | 29.82 | 4 |
Rentabilité EPS, % | -52.4 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 1.55 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 1.46 $ | 0 $ | 0 $ | 6.16 % | 0 % | 0 % |
common.calendar.number_days.30d | 1.58 $ | 1.37 $ | 1.55 $ | -1.9 % | 0 % | 0 % |
common.calendar.number_days.90d | 0.7901 $ | 0.78 $ | 1.62 $ | 96.18 % | 0 % | 0 % |
common.calendar.number_days.180d | 0.68 $ | 0.643 $ | 1.69 $ | 127.94 % | 0 % | 0 % |
common.calendar.number_days.1y | 1.19 $ | 0.643 $ | 1.69 $ | 30.25 % | 0 % | 0 % |
common.calendar.number_days.3y | 0.74 $ | 0.417 $ | 1.69 $ | 109.46 % | 0 % | 0 % |
common.calendar.number_days.5y | 5.57 $ | 0.417 $ | 12.26 $ | -72.17 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.417 $ | 0.417 $ | 12.26 $ | 371.7 % | 0 % | 0 % |
common.calendar.number_days.ytd | 0.6783 $ | 0.643 $ | 1.69 $ | 128.51 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Mr. Gabriele Marco Antonio Cerrone M.B.A. | Founder, Executive Chairman & Interim CEO | 817k | 1972 (53 année) |
Ms. Keeren Shah | Chief Financial Officer | 1976 (49 années) | |
Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer | ||
Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board | 1957 (68 années) |
Informations sur l'entreprise
Adresse: United Kingdom, London WS XJ, 14/15 Conduit Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.tizianalifesciences.com
Site web: https://www.tizianalifesciences.com